Abstract 32P
Background
There is an urgent need for biomarkers to tailor neoadjuvant treatment (NAT) in early triple-negative breast cancer (eTNBC). The characterization of circulating immune subsets could provide additional information which, added to other factors, may guide clinical decisions.
Methods
In this non-randomized prospective study, patients (pt) were treated with chemotherapy (docetaxel/carboplatin or sequential paclitaxel/carboplatin with doxorubicin/cyclophosphamide) with or without pembrolizumab. Immune cell subsets were analyzed in blood by multicolor flow cytometry (MFC). Adjusted paired 2-way ANOVA was done to compare immune subsets. In this first analysis, we report the frequencies of T cell subsets before and 21 days after completing NAT, and their relationship with pathological response.
Results
15 pt achieved pathological complete response (pCR) while 6 had a RCB score of II-III. Significant differences emerged between pCR (responders) and RCB (non-responders) after NAT (Table). Non-responders presented higher drops in total lymphocytes and CD4 cells (p > 0.05). All pt increased CD8 cells, being significant only in responders (p = 0.013). CD8 subsets exhibited distinct behavior based on response. After NAT, responders showed lower activated CD8 cells, whereas non-responders had the opposite trend. Post-NAT activated CD8 cells were lower in responders (p = 0.048). An opposing pattern was observed in the dynamics of the naïve and effector memory CD8 cells (p > 0.05). In the CD4 population, after NAT all pt showed decreased activated CD4 cells. These changes were deeper and significant in responders (p = 0.048). There were no significant differences between responders and non-responders in other CD4 subsets. Table: 32P
% of cells after NAT according to response
Baseline | Post-NAT | |||||
pCR | RCB II – III | P value | pCR | RCB II – III | P value | |
Lymphocytes | 19.1 | 17.9 | 0.99 | 18.1 | 11.5 | 0.44 |
CD4+ | 38,9 | 40,1 | 0.99 | 39.3 | 32.1 | 0.36 |
Activated | 68.3 | 78.5 | 0.5 | 54.6 | 72.6 | 0.045 |
Inactivated | 31.3 | 20.4 | 0.44 | 44.6 | 26.4 | 0.039 |
Naïve | 30.3 | 45.4 | 0.16 | 19.7 | 28.1 | 0.62 |
Effector | 2.1 | 2.2 | 0.99 | 3.1 | 5.1 | 0.99 |
Effector memory | 17.5 | 12.4 | 0.89 | 26.8 | 16.1 | 0.41 |
CD8+ | 16.9 | 13.2 | 0.9 | 26.2 | 20.9 | 0.63 |
Activated | 41.3 | 40 | 0.9 | 28.8 | 49.3 | 0.048 |
Inactivated | 45.5 | 48.9 | 0.9 | 53.3 | 39.7 | 0.32 |
Naïve | 21 | 23.4 | 0.9 | 13.1 | 29.9 | 0.15 |
Effector | 31.9 | 37.2 | 0.9 | 24.2 | 29.6 | 0.9 |
Effector memory | 31.9 | 31.1 | 0.9 | 36.3 | 20.1 | 0.18 |
Conclusions
In this study, there were significant differences in the peripheral T cell subsets based on NAT response, suggesting that there may be a systemic immune activation that could impact disease control. Further research is warranted to validate and amplify these observations.
Legal entity responsible for the study
The authors.
Funding
Instituto de Salud Carlos III (ISCIII) PI22/01346, cofinanciado por la Unión Europea.
Disclosure
I. Echavarria Diaz-Guardamino: Financial Interests, Personal, Advisory Board: Lilly, AstraZeneca; Financial Interests, Personal, Invited Speaker: Roche, Teva, Novartis, Pfizer, Lilly. Y. Jerez Gilarranz: Financial Interests, Personal, Invited Speaker: Daiichi Sankyo, Novartis, Roche, Pfizer. F. Moreno Anton: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Gilead; Financial Interests, Institutional, Research Grant: Pfizer. J.î García Saenz: Financial Interests, Personal, Advisory Board: Seagen, Gilead; Financial Interests, Personal, Speaker, Consultant, Advisor: Sanofi, Novartis, Celgene, Lilly, Eisai, AstraZeneca, MSD, Pierre Fabre, Daiichi Sankyo; Financial Interests, Personal and Institutional, Research Funding: AstraZeneca; Financial Interests, Personal, Other, Travel: Novartis, Roche, Pfizer. C. Bueno Muiño: Financial Interests, Personal, Invited Speaker: Novartis, Daiichi Sankyo, AstraZeneca, GSK, Lilly; Financial Interests, Personal, Advisory Board: Pfizer. T. Massarrah: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Roche, GSK; Financial Interests, Personal, Other, Travel: Novartis, AstraZeneca. M. Martin Jimenez: Financial Interests, Personal, Research Grant: PUMA; Financial Interests, Personal, Advisory Board: Lilly, Sanofi, Novartis, Seagen, Roche, AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Roche, Seagen, Lilly, AstraZeneca, Pfizer, Daiichi Sankyo; Financial Interests, Personal, Leadership Role: GEICAM, TRIO. S. Lopez-Tarruella Cobo: Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Roche, Pfizer, Veracyte, Pierre Fabre, Lilly, Seagen, Daiichi Sankyo, Europe GmbH, Gilead Sciences, MSD, GSK. All other authors have declared no conflicts of interest.
Resources from the same session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract
134P - Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract